Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma
Summary
The role of transarterial chemoembolization (TACE) as the standard therapy for intermediate-stage hepatocellular carcinoma (HCC) is being challenged by increasing studies which showed that liver resection (LR) is a safe and feasible procedure with better survival outcomes than TACE does. In light of this, the investigators have constructed a Markov model to simulate comparing LR and TACE in the treatment of intermediate-stage HCC. The results suggested that LR may provide survival benefit over TACE for the treatment of intermediate-stage HCC in cirrhotic patients. However, validating the simulated result by a study with higher quality (e.g. prospective clinical trial) would be of great value in providing a more convincing finding. Therefore, based on the established Markov model, the investigators aimed to prospectively compare the treatment efficacy and safety of LR with TACE for consecutive patients with intermediate-stage HCC.
Timeline
- Start
- 2014-03
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | 300 mg | Other |
| Comparator | Epirubicin | Small molecule | 50 mg | Other |
| Comparator | Epirubicin | Small molecule | 100 mg | Other |
| Comparator | Hydroxycamptothecin | Small molecule | 10 mg | Other |
| Comparator | Hydroxycamptothecin | Small molecule | 30 mg | Other |
| Comparator | Pirarubicin | Small molecule | 30 mg | Other |
| Comparator | Pirarubicin | Small molecule | 50 mg | Other |
| Comparator | fluorouracil | Small molecule | 500 mg | Other |
| Comparator | fluorouracil | Small molecule | 1000 mg | Other |
| Comparator | lipiodol | Unknown | 5 ml | Other |